Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK, and PD of BOS161721 in Healthy Subjects
NCT03036865Phase 1Completed
- Sponsor
- Boston Pharmaceuticals
- Start
- Jan 2017
- Primary completion
- Apr 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of avizakimab in systemic lupus erythematosus (SLE) (15 cohorts), sponsored by Boston Pharmaceuticals. Primary endpoints: Treatment-Emergent Serious Adverse Events up to 52 weeks, Treatment-Emergent Adverse Events up to 52 weeks and 8 more. Started Jan 2017; status: completed.
02
Drugs
avizakimab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT03036865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03036865.